Abstract
Platinum based chemotherapy (CT) with anti PD1/PDL1 is now a standard first line therapy in the management of mNSCLC without targetable driver mutations. PDL1 is expressed on tumour cells and PD1 is expressed on immune cells and these alternate mechanisms may alter clinical outcomes after tumour cell death. A network meta-analysis (NWM) showed anti PD1 + CT was superior to anti PDL1 + CT in overall survival (OS). However, only one anti PDL1, atezolizumab, was included in the analysis. More recently, several randomised controlled trials (RCT) involving newer anti PD1/PD L1 agents have been reported.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
